Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
20626402
DOI
10.1111/j.1755-5922.2010.00181.x
PII: CDR181
Knihovny.cz E-zdroje
- MeSH
- anticholesteremika škodlivé účinky terapeutické užití MeSH
- apolipoproteiny B metabolismus MeSH
- azetidiny škodlivé účinky terapeutické užití MeSH
- C-reaktivní protein metabolismus MeSH
- cholesterol krev MeSH
- diabetes mellitus 2. typu krev MeSH
- dvojitá slepá metoda MeSH
- ezetimib MeSH
- fluorbenzeny škodlivé účinky terapeutické užití MeSH
- hypercholesterolemie krev farmakoterapie MeSH
- kombinovaná farmakoterapie MeSH
- LDL-cholesterol krev MeSH
- léková rezistence MeSH
- lidé MeSH
- lipidy krev MeSH
- odds ratio MeSH
- pyrimidiny škodlivé účinky terapeutické užití MeSH
- rosuvastatin kalcium MeSH
- simvastatin škodlivé účinky terapeutické užití MeSH
- statiny škodlivé účinky terapeutické užití MeSH
- sulfonamidy škodlivé účinky terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Názvy látek
- anticholesteremika MeSH
- apolipoproteiny B MeSH
- azetidiny MeSH
- C-reaktivní protein MeSH
- cholesterol MeSH
- ezetimib MeSH
- fluorbenzeny MeSH
- LDL-cholesterol MeSH
- lipidy MeSH
- pyrimidiny MeSH
- rosuvastatin kalcium MeSH
- simvastatin MeSH
- statiny MeSH
- sulfonamidy MeSH
AIMS: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434). RESULTS: EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. CONCLUSIONS: Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.
Citace poskytuje Crossref.org